PAK2
Top inhibitors
| Drug | Inhibition % | Gini |
|---|---|---|
| Neratinib | 87.7 | 0.60 |
| Fostamatinib | 33.4 | 0.61 |
| Defactinib | 29.9 | 0.45 |
| Bosutinib | 29.6 | 0.55 |
| Vemurafenib | 29.4 | 0.60 |
| Midostaurin | 24.3 | 0.50 |
| Pacritinib | 21.4 | 0.45 |
| Pralsetinib | 15.6 | 0.64 |
| Ponatinib | 14.0 | 0.53 |
| Nilotinib | 13.1 | 0.77 |
| Ibrutinib | 12.8 | 0.72 |
| Abemaciclib | 12.6 | 0.56 |
| Pazopanib | 11.9 | 0.67 |
| Brigatinib | 11.9 | 0.51 |
| Tenalisib | 11.7 | 0.70 |
Known variants
Cancer associations
| Mutation | Cancer type | Organ | Source |
|---|---|---|---|
Y443N | Colon/Colorectal Cancer | Large Intestine | https://doi.org/10.1158/2159-8290.CD-12-0095 |
Y443N | carcinoma_ovary | Ovary | https://doi.org/10.1158/2159-8290.CD-12-0096 |